Health
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population, – EurekAlert
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called ”bad” cholesterol–by 50 percent in patients with severe…
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…
-
General21 hours agoVictorian school teacher charged with soliciting child abuse material
-
General12 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Noosa News18 hours agoFuel tanker driver killed in horror head-on crash near Blackbutt identified as beloved father-of-two
-
Noosa News16 hours agoPalestine protesters forced into last-minute reroute